TELA Bio Future Growth
Future criteria checks 5/6
TELA Bio is forecast to grow earnings and revenue by 66.7% and 21.7% per annum respectively while EPS is expected to grow by 67.9% per annum.
Key information
66.7%
Earnings growth rate
67.9%
EPS growth rate
| Medical Equipment earnings growth | 16.5% |
| Revenue growth rate | 21.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Jan 2025 |
Recent future growth updates
Recent updates
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely
Nov 09
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%
Aug 19Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?
Jul 03Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now
May 29TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward
May 23Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 24Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)
Mar 08TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?
Oct 07Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult
Jul 31TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Oct 02Tela Bio prices $32M common stock offering
Aug 16Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?
May 12TELA Bio - Follow Up With Management
Jan 14Our First Look At TELA Bio
Nov 04TELA Bio Plugging Away
Oct 25TELA Bio (TELA) Investor Presentation - Slideshow
May 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 148 | 13 | N/A | N/A | 1 |
| 12/31/2026 | 117 | -8 | N/A | N/A | 4 |
| 12/31/2025 | 94 | -26 | N/A | N/A | 4 |
| 12/31/2024 | 75 | -36 | N/A | N/A | 4 |
| 9/30/2024 | 69 | -42 | -46 | -45 | N/A |
| 6/30/2024 | 65 | -42 | -44 | -43 | N/A |
| 3/31/2024 | 63 | -40 | -44 | -44 | N/A |
| 12/31/2023 | 58 | -47 | -41 | -41 | N/A |
| 9/30/2023 | 53 | -44 | -42 | -41 | N/A |
| 6/30/2023 | 49 | -44 | -43 | -41 | N/A |
| 3/31/2023 | 45 | -45 | -44 | -42 | N/A |
| 12/31/2022 | 41 | -44 | -43 | -41 | N/A |
| 9/30/2022 | 38 | -43 | -40 | -39 | N/A |
| 6/30/2022 | 35 | -40 | -39 | -38 | N/A |
| 3/31/2022 | 32 | -36 | -33 | -32 | N/A |
| 12/31/2021 | 29 | -33 | -31 | -30 | N/A |
| 9/30/2021 | 27 | -32 | -28 | -28 | N/A |
| 6/30/2021 | 24 | -32 | -25 | -25 | N/A |
| 3/31/2021 | 20 | -30 | -26 | -26 | N/A |
| 12/31/2020 | 18 | -29 | -25 | -24 | N/A |
| 9/30/2020 | 17 | -28 | -25 | -25 | N/A |
| 6/30/2020 | 16 | -27 | -28 | -26 | N/A |
| 3/31/2020 | 16 | -29 | -27 | -25 | N/A |
| 12/31/2019 | 15 | -30 | -28 | -26 | N/A |
| 9/30/2019 | 13 | -32 | -28 | -24 | N/A |
| 6/30/2019 | 11 | -30 | -24 | -22 | N/A |
| 3/31/2019 | 10 | -28 | -24 | -22 | N/A |
| 12/31/2018 | 8 | -30 | -21 | -20 | N/A |
| 12/31/2017 | 4 | -27 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TELA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: TELA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TELA is expected to become profitable in the next 3 years.
Revenue vs Market: TELA's revenue (21.7% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: TELA's revenue (21.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TELA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 12:44 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TELA Bio, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyle Rose | Canaccord Genuity |
| William Plovanic | Canaccord Genuity |
| Caitlin Cronin | Canaccord Genuity |